Zyprexa

Delirium, Delusional Parasitosis, Schizophrenia + 11 more

Treatment

8 FDA approvals

20 Active Studies for Zyprexa

What is Zyprexa

Olanzapine

The Generic name of this drug

Treatment Summary

Olanzapine is an antipsychotic medication that belongs to a class of drugs known as atypical or second-generation antipsychotics. It was developed in the 1990s and is known for its effectiveness, low risk of side effects, and reduced risk of drug interactions. It is similar to clozapine but contains two additional methyl groups and does not have a chloride moiety. Olanzapine was approved by the FDA in 1996 and is sold under the brand name Zyprexa.

Zyprexa

is the brand name

image of different drug pills on a surface

Zyprexa Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Zyprexa

Olanzapine

1996

546

Approved as Treatment by the FDA

Olanzapine, otherwise known as Zyprexa, is approved by the FDA for 8 uses which include Mental Depression and Bipolar Disorder .

Mental Depression

Used to treat Acute Depressive Episode in combination with Fluoxetine

Bipolar Disorder

Used to treat Bipolar 1 Disorder in combination with Fluoxetine

Bipolar Disorder

Used to treat Bipolar Disorder With Manic or Mixed Episodes in combination with Lithium cation

Unipolar Depression

Used to treat Major depressive disorder, recurrent episode in combination with Fluoxetine

Bipolar Disorder With Manic or Mixed Episodes

Used to treat Bipolar Disorder With Manic or Mixed Episodes in combination with Lithium cation

Bipolar 1 Disorder

Used to treat Bipolar 1 Disorder in combination with Fluoxetine

Acute Depressive Episode

Used to treat Acute Depressive Episode in combination with Fluoxetine

Major depressive disorder, recurrent episode

Used to treat Major depressive disorder, recurrent episode in combination with Fluoxetine

Effectiveness

How Zyprexa Affects Patients

Olanzapine is a drug used to treat schizophrenia and bipolar disorder in adults and adolescents. It works by targeting the dopamine D2 receptor and the serotonin 5HT2A receptor, which helps to reduce hallucinations, delusions, disorganized speech and behavior, and anhedonia (loss of pleasure). Olanzapine also has been shown to help control chemotherapy-induced nausea and vomiting. In clinical trials, it was observed that 84% of individuals had a complete response on the delay phase, with over 80% control of emesis.

How Zyprexa works in the body

Olanzapine works by blocking multiple receptors in the brain, such as dopamine, serotonin, adrenaline and histamine receptors. The blocking of dopamine receptors in the mesolimbic pathway plays a key role in preventing dopamine from having an effect at the post-synaptic receptor. Olanzapine also acts on serotonin 5HT2A receptors in the frontal cortex to reduce unpleasant side effects.

When to interrupt dosage

The prescribed amount of Zyprexa is contingent upon the diagnosed condition, including Schizophrenia, Bipolar Disorder and Delirium. The quantity of dosage is based on the administration process (e.g. Kit - Intramuscular or Tablet, film coated - Oral) elucidated in the table below.

Condition

Dosage

Administration

Delirium

2.5 mg, , 5.0 mg, 20.0 mg, 15.0 mg, 10.0 mg, 10.0 mg/mL, 7.5 mg, 3.0 mg, 6.0 mg, 12.0 mg, 210.0 mg, 300.0 mg, 405.0 mg, 405.0 mg/mL, 300.0 mg/mL, 210.0 mg/mL

, Oral, Tablet, film coated - Oral, Tablet, film coated, Injection, powder, for solution - Intramuscular, Intramuscular, Injection, powder, for solution, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Injection, powder, lyophilized, for solution - Intramuscular, Injection, powder, lyophilized, for solution, Powder, for solution, Powder, for solution - Intramuscular, Tablet, coated, Tablet, coated - Oral, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Kit, Kit - Intramuscular

Schizophrenia

2.5 mg, , 5.0 mg, 20.0 mg, 15.0 mg, 10.0 mg, 10.0 mg/mL, 7.5 mg, 3.0 mg, 6.0 mg, 12.0 mg, 210.0 mg, 300.0 mg, 405.0 mg, 405.0 mg/mL, 300.0 mg/mL, 210.0 mg/mL

, Oral, Tablet, film coated - Oral, Tablet, film coated, Injection, powder, for solution - Intramuscular, Intramuscular, Injection, powder, for solution, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Injection, powder, lyophilized, for solution - Intramuscular, Injection, powder, lyophilized, for solution, Powder, for solution, Powder, for solution - Intramuscular, Tablet, coated, Tablet, coated - Oral, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Kit, Kit - Intramuscular

Schizophrenia

2.5 mg, , 5.0 mg, 20.0 mg, 15.0 mg, 10.0 mg, 10.0 mg/mL, 7.5 mg, 3.0 mg, 6.0 mg, 12.0 mg, 210.0 mg, 300.0 mg, 405.0 mg, 405.0 mg/mL, 300.0 mg/mL, 210.0 mg/mL

, Oral, Tablet, film coated - Oral, Tablet, film coated, Injection, powder, for solution - Intramuscular, Intramuscular, Injection, powder, for solution, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Injection, powder, lyophilized, for solution - Intramuscular, Injection, powder, lyophilized, for solution, Powder, for solution, Powder, for solution - Intramuscular, Tablet, coated, Tablet, coated - Oral, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Kit, Kit - Intramuscular

Bipolar Disorder

2.5 mg, , 5.0 mg, 20.0 mg, 15.0 mg, 10.0 mg, 10.0 mg/mL, 7.5 mg, 3.0 mg, 6.0 mg, 12.0 mg, 210.0 mg, 300.0 mg, 405.0 mg, 405.0 mg/mL, 300.0 mg/mL, 210.0 mg/mL

, Oral, Tablet, film coated - Oral, Tablet, film coated, Injection, powder, for solution - Intramuscular, Intramuscular, Injection, powder, for solution, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Injection, powder, lyophilized, for solution - Intramuscular, Injection, powder, lyophilized, for solution, Powder, for solution, Powder, for solution - Intramuscular, Tablet, coated, Tablet, coated - Oral, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Kit, Kit - Intramuscular

Post Traumatic Stress Disorder

2.5 mg, , 5.0 mg, 20.0 mg, 15.0 mg, 10.0 mg, 10.0 mg/mL, 7.5 mg, 3.0 mg, 6.0 mg, 12.0 mg, 210.0 mg, 300.0 mg, 405.0 mg, 405.0 mg/mL, 300.0 mg/mL, 210.0 mg/mL

, Oral, Tablet, film coated - Oral, Tablet, film coated, Injection, powder, for solution - Intramuscular, Intramuscular, Injection, powder, for solution, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Injection, powder, lyophilized, for solution - Intramuscular, Injection, powder, lyophilized, for solution, Powder, for solution, Powder, for solution - Intramuscular, Tablet, coated, Tablet, coated - Oral, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Kit, Kit - Intramuscular

Tourette Syndrome

2.5 mg, , 5.0 mg, 20.0 mg, 15.0 mg, 10.0 mg, 10.0 mg/mL, 7.5 mg, 3.0 mg, 6.0 mg, 12.0 mg, 210.0 mg, 300.0 mg, 405.0 mg, 405.0 mg/mL, 300.0 mg/mL, 210.0 mg/mL

, Oral, Tablet, film coated - Oral, Tablet, film coated, Injection, powder, for solution - Intramuscular, Intramuscular, Injection, powder, for solution, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Injection, powder, lyophilized, for solution - Intramuscular, Injection, powder, lyophilized, for solution, Powder, for solution, Powder, for solution - Intramuscular, Tablet, coated, Tablet, coated - Oral, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Kit, Kit - Intramuscular

Mental Depression

2.5 mg, , 5.0 mg, 20.0 mg, 15.0 mg, 10.0 mg, 10.0 mg/mL, 7.5 mg, 3.0 mg, 6.0 mg, 12.0 mg, 210.0 mg, 300.0 mg, 405.0 mg, 405.0 mg/mL, 300.0 mg/mL, 210.0 mg/mL

, Oral, Tablet, film coated - Oral, Tablet, film coated, Injection, powder, for solution - Intramuscular, Intramuscular, Injection, powder, for solution, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Injection, powder, lyophilized, for solution - Intramuscular, Injection, powder, lyophilized, for solution, Powder, for solution, Powder, for solution - Intramuscular, Tablet, coated, Tablet, coated - Oral, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Kit, Kit - Intramuscular

Acute Agitation

2.5 mg, , 5.0 mg, 20.0 mg, 15.0 mg, 10.0 mg, 10.0 mg/mL, 7.5 mg, 3.0 mg, 6.0 mg, 12.0 mg, 210.0 mg, 300.0 mg, 405.0 mg, 405.0 mg/mL, 300.0 mg/mL, 210.0 mg/mL

, Oral, Tablet, film coated - Oral, Tablet, film coated, Injection, powder, for solution - Intramuscular, Intramuscular, Injection, powder, for solution, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Injection, powder, lyophilized, for solution - Intramuscular, Injection, powder, lyophilized, for solution, Powder, for solution, Powder, for solution - Intramuscular, Tablet, coated, Tablet, coated - Oral, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Kit, Kit - Intramuscular

Unipolar Depression

2.5 mg, , 5.0 mg, 20.0 mg, 15.0 mg, 10.0 mg, 10.0 mg/mL, 7.5 mg, 3.0 mg, 6.0 mg, 12.0 mg, 210.0 mg, 300.0 mg, 405.0 mg, 405.0 mg/mL, 300.0 mg/mL, 210.0 mg/mL

, Oral, Tablet, film coated - Oral, Tablet, film coated, Injection, powder, for solution - Intramuscular, Intramuscular, Injection, powder, for solution, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Injection, powder, lyophilized, for solution - Intramuscular, Injection, powder, lyophilized, for solution, Powder, for solution, Powder, for solution - Intramuscular, Tablet, coated, Tablet, coated - Oral, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Kit, Kit - Intramuscular

Acute Coryza

2.5 mg, , 5.0 mg, 20.0 mg, 15.0 mg, 10.0 mg, 10.0 mg/mL, 7.5 mg, 3.0 mg, 6.0 mg, 12.0 mg, 210.0 mg, 300.0 mg, 405.0 mg, 405.0 mg/mL, 300.0 mg/mL, 210.0 mg/mL

, Oral, Tablet, film coated - Oral, Tablet, film coated, Injection, powder, for solution - Intramuscular, Intramuscular, Injection, powder, for solution, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Injection, powder, lyophilized, for solution - Intramuscular, Injection, powder, lyophilized, for solution, Powder, for solution, Powder, for solution - Intramuscular, Tablet, coated, Tablet, coated - Oral, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Kit, Kit - Intramuscular

Delusional Parasitosis

2.5 mg, , 5.0 mg, 20.0 mg, 15.0 mg, 10.0 mg, 10.0 mg/mL, 7.5 mg, 3.0 mg, 6.0 mg, 12.0 mg, 210.0 mg, 300.0 mg, 405.0 mg, 405.0 mg/mL, 300.0 mg/mL, 210.0 mg/mL

, Oral, Tablet, film coated - Oral, Tablet, film coated, Injection, powder, for solution - Intramuscular, Intramuscular, Injection, powder, for solution, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Injection, powder, lyophilized, for solution - Intramuscular, Injection, powder, lyophilized, for solution, Powder, for solution, Powder, for solution - Intramuscular, Tablet, coated, Tablet, coated - Oral, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Kit, Kit - Intramuscular

Bipolar Disorder

2.5 mg, , 5.0 mg, 20.0 mg, 15.0 mg, 10.0 mg, 10.0 mg/mL, 7.5 mg, 3.0 mg, 6.0 mg, 12.0 mg, 210.0 mg, 300.0 mg, 405.0 mg, 405.0 mg/mL, 300.0 mg/mL, 210.0 mg/mL

, Oral, Tablet, film coated - Oral, Tablet, film coated, Injection, powder, for solution - Intramuscular, Intramuscular, Injection, powder, for solution, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Injection, powder, lyophilized, for solution - Intramuscular, Injection, powder, lyophilized, for solution, Powder, for solution, Powder, for solution - Intramuscular, Tablet, coated, Tablet, coated - Oral, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Kit, Kit - Intramuscular

Alzheimer's Disease

2.5 mg, , 5.0 mg, 20.0 mg, 15.0 mg, 10.0 mg, 10.0 mg/mL, 7.5 mg, 3.0 mg, 6.0 mg, 12.0 mg, 210.0 mg, 300.0 mg, 405.0 mg, 405.0 mg/mL, 300.0 mg/mL, 210.0 mg/mL

, Oral, Tablet, film coated - Oral, Tablet, film coated, Injection, powder, for solution - Intramuscular, Intramuscular, Injection, powder, for solution, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Injection, powder, lyophilized, for solution - Intramuscular, Injection, powder, lyophilized, for solution, Powder, for solution, Powder, for solution - Intramuscular, Tablet, coated, Tablet, coated - Oral, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Kit, Kit - Intramuscular

Bipolar Disorder

2.5 mg, , 5.0 mg, 20.0 mg, 15.0 mg, 10.0 mg, 10.0 mg/mL, 7.5 mg, 3.0 mg, 6.0 mg, 12.0 mg, 210.0 mg, 300.0 mg, 405.0 mg, 405.0 mg/mL, 300.0 mg/mL, 210.0 mg/mL

, Oral, Tablet, film coated - Oral, Tablet, film coated, Injection, powder, for solution - Intramuscular, Intramuscular, Injection, powder, for solution, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Injection, powder, lyophilized, for solution - Intramuscular, Injection, powder, lyophilized, for solution, Powder, for solution, Powder, for solution - Intramuscular, Tablet, coated, Tablet, coated - Oral, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Kit, Kit - Intramuscular

Warnings

There are 20 known major drug interactions with Zyprexa.

Common Zyprexa Drug Interactions

Drug Name

Risk Level

Description

Acenocoumarol

Major

The metabolism of Acenocoumarol can be decreased when combined with Olanzapine.

Acepromazine

Major

Olanzapine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Acepromazine.

Aclidinium

Major

The risk or severity of adverse effects can be increased when Olanzapine is combined with Aclidinium.

Alfuzosin

Major

Olanzapine may increase the hypotensive activities of Alfuzosin.

Amisulpride

Major

Olanzapine may increase the antipsychotic activities of Amisulpride.

Zyprexa Toxicity & Overdose Risk

Symptoms of olanzapine toxicity include drowsiness, dilated pupils, difficulty breathing, low blood pressure, muscle stiffness, and dry mouth. The maximum recommended dose is 300 mg, although higher doses have been reported to cause agitation, slurred speech, rapid heartbeat, and reduced consciousness. In extreme cases, olanzapine overdose can be fatal. Treatment for olanzapine overdose includes ensuring adequate oxygen and ventilation, as well as administering activated charcoal and laxatives. In animal studies, olanzapine has been linked to an increased risk of liver and breast tumors, as well as decreased fertility in males

image of a doctor in a lab doing drug, clinical research

Zyprexa Novel Uses: Which Conditions Have a Clinical Trial Featuring Zyprexa?

At present, 578 active trials are being conducted to investigate the potential of Zyprexa in providing relief from Schizophrenia, Post Traumatic Stress Disorder and Delusional Parasitosis.

Condition

Clinical Trials

Trial Phases

Schizophrenia

94 Actively Recruiting

Phase 3, Not Applicable, Early Phase 1, Phase 4, Phase 1, Phase 2

Post Traumatic Stress Disorder

232 Actively Recruiting

Early Phase 1, Not Applicable, Phase 3, Phase 2, Phase 4, Phase 1

Bipolar Disorder

0 Actively Recruiting

Schizophrenia

30 Actively Recruiting

Early Phase 1, Not Applicable, Phase 4

Mental Depression

2 Actively Recruiting

Phase 2, Not Applicable

Delirium

22 Actively Recruiting

Phase 2, Phase 3, Not Applicable, Phase 4, Early Phase 1

Unipolar Depression

46 Actively Recruiting

Not Applicable, Early Phase 1, Phase 3, Phase 2, Phase 1

Bipolar Disorder

0 Actively Recruiting

Bipolar Disorder

0 Actively Recruiting

Delusional Parasitosis

0 Actively Recruiting

Alzheimer's Disease

37 Actively Recruiting

Phase 4, Phase 2, Phase 3, Not Applicable, Phase 1

Acute Coryza

0 Actively Recruiting

Acute Agitation

0 Actively Recruiting

Tourette Syndrome

0 Actively Recruiting

Zyprexa Reviews: What are patients saying about Zyprexa?

5

Patient Review

12/28/2020

Zyprexa for Depression associated with Bipolar Disorder, Adjunct Treatment

I've been on this medication for a couple of months now, and it has really helped me to manage my anxiety. It's made a world of difference for me, and I would recommend it to anyone struggling with similar issues.

5

Patient Review

5/21/2022

Zyprexa for Additional Medications to Treat Depression

If you're struggling with depression and anxiety, I would highly recommend this medication. In addition to my antidepressant, it's really helped me with managing my anxiety levels and getting better sleep. Just be aware that you may see some weight gain as a side effect.

4.3

Patient Review

1/15/2021

Zyprexa for Manic-Depression

Zyprexa was an absolute lifesaver for me. I had been struggling with suicidal thoughts for months, and they disappeared the very next day after taking this medication. It's not intended to be a long-term solution, but it definitely helped me in the short term. The main downside is that it made me feel incredibly drowsy and gave me a voracious appetite; however, I believe that the pros outweigh the cons in this case.

4

Patient Review

5/23/2021

Zyprexa for Depression associated with Bipolar Disorder, Adjunct Treatment

I've been taking this medication on and off for years, and it does a great job of curbing the paranoia and psychosis. However, it can make you feel exhausted and coming off of it is really tough - expect severe depression and suicidal thoughts. I hate that I may need to be on this medication for the rest of my life just to have any sense of normalcy.

3.7

Patient Review

8/14/2022

Zyprexa for Mania associated with Bipolar Disorder

I started on 5mg, which made me sleepy for a few months. But it stopped the crazy thoughts and I didn't gain any weight. I'm a very fussy eater and hit the gym 5 days a week so I decided to see if I could get away with microdosing. So far, 0.625 mg is still working for me.

3.7

Patient Review

7/31/2021

Zyprexa for Depression associated with Bipolar Disorder, Adjunct Treatment

Zyprexa is a powerful drug and I found that just a quarter of the 5mg wafer was effective in reducing negative thoughts and anxiety, as well as rumination about hateful things that have happened. Obviously, if you start to feel like a zombie, cut the dose down. It has the potential to make you hungry but you have to stay away from junk food.

2.7

Patient Review

4/26/2021

Zyprexa for Additional Medications to Treat Depression

Overall, this made me feel worse. I gained a ton of weight and my lab work had a lot of problems. I wouldn't recommend it to anyone with mental health issues because it will make them worse.

1.7

Patient Review

6/3/2021

Zyprexa for Additional Medications to Treat Depression

This pill was ineffective at treating my psychosis caused by Ptednisone

1

Patient Review

1/28/2021

Zyprexa for Schizophrenia

Unfortunately, this medication caused me to gain weight that I could not get rid of. Additionally, I got stretch marks and felt bloated all the time. If you stop taking it, you might also experience insomnia.

1

Patient Review

11/28/2021

Zyprexa for Depression associated with Bipolar Disorder, Adjunct Treatment

Just a warning: if you don't want to be medicated with this drug, it's important to not lose your temper. Be careful of the signs in yourself and your children, and find ways to cope before it becomes a problem.

1

Patient Review

4/18/2021

Zyprexa for Mental Disorder with Loss of Normal Personality & Reality

Do not take this medication. It made my hallucinations worse and caused me to black out for days.

1

Patient Review

4/28/2022

Zyprexa for Additional Medications to Treat Depression

I was originally taking 5mg of this medication, but my doctor suggested I lower the dose to 2.5mg. For a little while, it worked well. But then, within a month, things took a turn for the worse. I was sleep-deprived and in a terrible mood all the time. The only upside was that I lost some weight; but overall, this medicine has been more of a curse than a blessing.

1

Patient Review

7/6/2022

Zyprexa for Bipolar I Disorder with Most Recent Episode Mixed

My neurologist told me to stop taking this medication Zyprexa because it showed signs of giving me Parkinson's. I had to be treated for two years before they realized I never actually had the disease; it was just a side effect of the drug. So, in conclusion, don't take this med if you can help it.

1

Patient Review

4/5/2022

Zyprexa for Schizophrenia

I would advise against taking this medication. It caused me to gain a lot of weight, and it's taken over a decade to lose most of it. There are lots of side effects that make you feel constantly hungry and emotionless.

1

Patient Review

6/5/2022

Zyprexa for Bipolar Disorder in Remission

The side effect I experienced was my legs twitching.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about zyprexa

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What are side effects of Zyprexa?

",increased sweating or urination, diarrhea, or constipation; and, very rare side effects (occurring in less than 1 in 1,000 people), coma and death.

The following are potential side effects of the medication, which are more likely to occur in teenagers: weight gain, increased appetite, headache, dizziness, drowsiness, feeling tired or restless, problems with speech or memory, tremors or shaking, numbness or tingly feeling, changes in personality, dry mouth, or increased salivation. Increased sweating or urination, diarrhea, or constipation are also potential side effects, though they are less common. Very rare side effects, which occur in less than 1 in 1,000 people, include coma and death."

Answered by AI

Is Zyprexa a mood stabilizer?

"Olanzapine is a mood stabilizer that is similar to lithium, certain anticonvulsants, and some other antipsychotics. Olanzapine can also help to treat depression when combined with fluoxetine."

Answered by AI

What is the drug Zyprexa used for?

"Olanzapine is a medication that is used to treat schizophrenia by working on the brain. It is classified as a second generation antipsychotic (SGA) or atypical antipsychotic. Olanzapine balances the levels of dopamine and serotonin in order to improve thinking, mood, and behavior."

Answered by AI

Is Zyprexa for anxiety or depression?

"Lithium is a medication that is taken for long periods of time in order to treat episodes of mania and depression. It is often prescribed for a minimum of six months. Lithium works as a mood stabilizer by helping to even out moods and control symptoms of both mania and depression. Olanzapine is another medication that can help with symptoms of mania."

Answered by AI

Clinical Trials for Zyprexa

Image of Stanford University School of Medicine in Stanford, United States.

BEAR Program for Suicidal Thoughts

18 - 75
Female
Stanford, CA

The current study aims to test the feasibility of a new form of group therapy for women who have a history of interpersonal trauma and current suicidal ideation. The Building Empowerment and Resilience (BEAR) Therapeutic group has been adapted for women who have experienced trauma and have current suicidal ideation. It incorporates psychological skills, psychoeducation about trauma and gender-based violence, and physical self-defense training, all within a therapeutic process. It will be implemented with women who have experienced interpersonal trauma (physical, sexual, or emotional abuse/neglect) and experience various mental health difficulties, including suicidal ideation. We aim to assess the feasibility to recruit and implement the BEAR group. Our ultimate aim is to assess whether the program can effect self-efficacy and suicidal ideation.

Waitlist Available
Has No Placebo

Stanford University School of Medicine

Jennifer Keller, PhD

Image of White River Junction VA Hospital in White River Junction, United States.

Transcranial Magnetic Stimulation for PTSD

19 - 70
All Sexes
White River Junction, VT

With this research investigators hope to begin to understand how rTMS can improve posttraumatic stress disorder (PTSD) symptoms. TMS improves PTSD through two interrelated mechanisms: change in brain limbic system function and change in systemic inflammatory activation. Participants who decide to join this study, will receive ten rTMS treatments. All participants will undergo a 40-minute rTMS procedure with a member of the study team 10 times over 2-4 weeks. Participants will undergo fMRI scans of the head in order to help researchers better understand potential effects of rTMS on brain activity. In addition, participants will be asked to give two breath and blood samples to look for signs of general inflammation.

Recruiting
Has No Placebo

White River Junction VA Hospital

Bradley Watts

Have you considered Zyprexa clinical trials?

We made a collection of clinical trials featuring Zyprexa, we think they might fit your search criteria.
Go to Trials
Image of Pavillon Adrien-Pinard (SU) in Montreal, Canada.

Cognitive Remediation for PTSD

18 - 45
All Sexes
Montreal, Canada

The goal of this clinical trial is to evaluate whether computer-based brain training can help adults with post-traumatic stress disorder (PTSD). Individuals with PTSD often experience difficulties with memory, attention, concentration, and problem-solving, which can significantly affect their daily lives, work performance, and overall quality of life. These cognitive challenges can hinder trauma recovery and reduce the effectiveness of standard PTSD treatments. The main questions this study seeks to address are: Does specialized brain training improve PTSD symptoms compared to regular computer games? Does brain training enhance cognitive functions such as memory, attention, processing speed, and executive functioning? Does brain training improve quality of life and daily functioning? Do participants' self-efficacy and perceived social support influence treatment outcomes? Researchers will compare two approaches: a specialized cognitive training program (HAPPYneuron Pro) with strategy teachings and quality-of-life discussions, versus engaging computer games with quality-of-life discussions, to determine which is more effective for people with PTSD. Study Design Participants will be randomly assigned to one of two groups for an 8-week program: Cognitive remediation training group: Complete computerized cognitive exercises and strategy teachings specifically designed to strengthen memory, attention, and executive functions, combined with quality-of-life discussions. Control group: Complete engaging computer games combined with quality-of-life discussions. Schedule Both groups will follow the same schedule: One online session per week, in small and consistent groups of 6 participants. Each 60-minute session consists of 30 minutes of computer activities followed by 45 minutes of group discussion. One at-home individual homework exercise per week (30 minutes at home). Total time commitment: 1h45 per week for 8 weeks. Assessments All participants will complete three comprehensive assessment sessions: before treatment, immediately after the 8-week program, and 3 months later. Assessments include neuropsychological testing and questionnaires on PTSD symptoms, depression, anxiety, quality of life, satisfaction with life, social support, cognitive failures, and self-efficacy. Significance This research evaluates a new, accessible and remotely deliverable approach for PTSD treatment. Current evidence-based treatments often do not directly target the cognitive impairments experienced by many individuals with PTSD. Compensation Participants will receive $35 for each completed assessment (maximum $105). Control group participants will gain access to the cognitive remediation training program after completing their participation.

Recruiting
New This Month

Pavillon Adrien-Pinard (SU)

Have you considered Zyprexa clinical trials?

We made a collection of clinical trials featuring Zyprexa, we think they might fit your search criteria.
Go to Trials
Image of Emory Brain Health Center in Atlanta, United States.

MDMA-Assisted Therapy for PTSD

21 - 70
All Sexes
Atlanta, GA

The goal of this clinical trial is to investigate the efficacy of 3,4-methylenedioxy-methamphetamine hydrochloride (MDMA) combined with Massed Prolonged Exposure (PE) therapy for the treatment of posttraumatic stress disorder (PTSD) in adult participants diagnosed with PTSD. This randomized, placebo-controlled trial will enroll 95 participants. The main questions it aims to answer are: * Does the combination of PE + MDMA lead to greater reduction in PTSD symptom severity from pre-treatment to one-month follow-up compared to PE + placebo? * Does PE + MDMA improve response efficiency and durability of PTSD symptom improvement compared to PE + placebo? * Does MDMA + PE enhance extinction retention and reduce amygdala threat reactivity, and are these changes associated with improved PTSD outcomes? Participants will: * Receive 10 sessions of Massed Prolonged Exposure therapy over two weeks * Be administered either 100 mg of MDMA or a placebo at Visit 2 * Undergo blinded independent evaluator assessments using the Clinician-Administered PTSD Scale for DSM-5-R (CAPS-5-R) at the one-month posttreatment follow-up

Phase 2
Waitlist Available

Emory Brain Health Center

Jessica Maples-Keller, PhD

Image of University of Colorado Anschutz Medical Campus in Aurora, United States.

Senseye Diagnostic Tool for Post-Traumatic Stress Disorder

18+
All Sexes
Aurora, CO

The goal of the REVEAL PTSD study is to test how well the Senseye DT works as a diagnostic test for Post-traumatic Stress Disorder (PTSD) in adults 18 and older who are experiencing one or more symptoms that might be related to PTSD. The Senseye DT is software as a medical device (SaMD) and is an iPhone app that administers a series of simple tasks on the phone while recording video during the tasks through the front-facing camera. The videos are analyzed by a a Machine Learning (ML) algorithm to identify physiologic signals that might be indicative of PTSD. Data collected in this study will be used to train and tune the ML algorithm, then test it for accuracy. The main questions this study aims to answer are: 1. How accurate is the Senseye DT in detecting PTSD compared to structured clinical interviews, the current clinical standard for diagnostic testing? 2. How accurately does the Senseye DT predict PTSD severity? 3. How fast is the Senseye DT to use compared to structured clinical interviews? Participants will attend a virtual screening visit via video call to determine eligibility and consent to participate. Once enrolled, participants will attend 2 or 3 additional study visits: * Visit 1: A virtual visit where standard mental health assessments will be given by clinical raters trained in mental health and administering these structured clinical interviews. These assessments include the Structured Interview Guide for the Montgomery-Asburg Depression Rating Scale (SIGMA), the Structured Interview Guide for the Hamilton Anxiety Scale (SIGH-A), and the MINI International Neurodiagnostic Interview. The Clinician-Administered PTSD Scale for DSM-5 Revised Version (CAPS-5-R) may also be conducted, if randomly selected. * Visit 2: A visit to use the Senseye DT. For participants near one of the study's physical site locations, this visit will be done in person at the site. For all others, this visit will be conducted virtually. * Visit 3: For participants not randomly selected to have the CAPS-5-R administered at Visit 1, a third and final visit will be scheduled for this assessment. This visit will be conducted virtually. The total expected participation time for enrolled participants is 6-7 hours over the course of 2-3 weeks.

Phase 3
Waitlist Available

University of Colorado Anschutz Medical Campus (+3 Sites)

Senseye, Inc.

Have you considered Zyprexa clinical trials?

We made a collection of clinical trials featuring Zyprexa, we think they might fit your search criteria.
Go to Trials